ProMIS Neurosciences is a clinical-stage biotechnology company that focuses on developing antibody therapeutics targeting toxic misfolded proteins associated with neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company employs a proprietary target discovery engine that utilizes advanced computational technologies, specifically ProMIS™ and Collective Coordinates, to identify and predict toxic misfolded proteins. This innovative approach allows ProMIS to create highly selective therapeutic antibodies, such as PMN310, which is designed to target only the toxic oligomers of amyloid-beta implicated in AD, while avoiding non-toxic forms of the protein. This selectivity is crucial for minimizing potential side effects and enhancing the therapeutic efficacy of their treatments.

In addition to PMN310, ProMIS is also developing other therapeutic candidates, including PMN267, which targets misfolded TDP-43 for ALS, and is exploring vaccine strategies aimed at inducing immune responses against toxic amyloid-beta oligomers. The company’s research is grounded in a deep understanding of protein misfolding diseases, and it aims to leverage its proprietary technologies to create a robust pipeline of therapies that address the underlying causes of these debilitating conditions. By focusing on the specific misfolded proteins that drive disease progression, ProMIS Neurosciences is positioned to make significant advancements in the treatment of neurodegenerative diseases.

Canada

ProMIS Neurosciences, Inc. is a leading development-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. The company is focused on the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy through the development of antibody therapeutics and diagnostics. ProMIS Neurosciences is publicly traded on the Toronto Stock Exchange.

Central Nervous System (CNS)

Nervous System Diseases

ProMIS Neurosciences

Alzheimer's disease

Neurodegenerative disease

<p class="font_8">PMN310, ProMIS’ lead compound, is a humanized IgG1 antibody directed against toxic amyloid beta oligomers (AβO) that are believed to be a major driver of AD.</p>

ProMIS Neurosciences

Company Details